Science as a business rule: the impact of Law No. 15,524/2026 on private clinics and hospitals

17.11.2026
.
In September 2026, the enactment of Law No. 15,524 changed a fundamental rule in how private healthcare operates in Brazil. Until then, health surveillance looked almost exclusively at the physical infrastructure of establishments—cleaning, sterilization, waste disposal, and building safety. Now, Anvisa is tasked with inspecting the scientific evidence and efficacy of the treatments offered.

But what does this mean, in practice, for boards of directors, clinic owners, and hospital executives?

It means that offering treatments or infusions without a solid scientific basis is no longer merely a debate about medical autonomy. It has become a direct business risk.

The danger to reputation

The law provides for daily fines of R$ 5,000.00 for those who fail to comply with the new standards. However, the greatest financial impact does not lie in the amount of the fine, but in the impact on the institution and the physician.
The new rule requires that the results of the quality evaluations conducted by Anvisa be disclosed to the public. For a healthcare institution, having its name exposed on an official list as a provider of services without proven efficacy is a massive blow to its reputation. In addition to driving patients away, this exposure can trigger lawsuits and severe penalties from the National Supplementary Health Agency (ANS) and consumer protection agencies, as well as potential liability claims filed by the patients themselves.

How to protect the institution?

Faced with this scenario, corporate integrity programs—which in recent years have focused heavily on the General Data Protection Law (LGPD) and fraud prevention—need to go a step further. Evidence-based clinical governance must become part of day-to-day management.
To protect the business and patients, we recommend that healthcare institution leaders adopt three practical measures:
  • Review the service portfolio: It is necessary to map all procedures, therapies, and packages offered by the clinic or hospital. Each must be backed by serious studies and approved by medical councils. Anything that is purely experimental and lacks robust medical literature must be urgently reviewed.
  • Empower the Medical Directorate: The Technical Director and the institution’s ethics committees need full autonomy and management support. The introduction of a new treatment or technology suggested by the clinical staff cannot be approved solely based on commercial appeal; it must undergo a strict analysis of safety and scientific validity.
  • Update contracts and internal rules: Hospital bylaws and contracts signed with partner physicians must make it clear that “medical autonomy” has legal limits within the institution. If a professional performs practices without scientific backing on the clinic’s premises, the company must have clear contractual mechanisms to protect itself and hold the responsible party accountable.
Complying with this new law does not mean stifling medicine, but rather protecting the company and valuing what is most sacred in healthcare: patient safety. Institutions that embrace transparency and science as non-negotiable values strengthen their brands and earn lasting trust from the market.
Cammarota & Abreu Advogados closely follows the transformations in the supplementary healthcare sector and has extensive experience in connecting business ethics to corporate legal security. Our team is available to managers and directors to discuss the best way to adapt their institutions’ processes to this new scenario.
Share

Related posts

Rua Ministro Godoi, 478, 4th Floor
São Paulo, SP 05015-000, Brazil